唾液腺導管癌に対するトラスツズマブの使用経験

DOI Web Site 参考文献7件
  • 小山 哲史
    鳥取大学感覚運動医学講座　耳鼻咽喉・頭頸部外科学分野
  • 藤原 和典
    鳥取大学感覚運動医学講座　耳鼻咽喉・頭頸部外科学分野
  • 福原 隆宏
    鳥取大学感覚運動医学講座　耳鼻咽喉・頭頸部外科学分野
  • 竹内 英二
    鳥取大学感覚運動医学講座　耳鼻咽喉・頭頸部外科学分野
  • 北野 博也
    鳥取大学感覚運動医学講座　耳鼻咽喉・頭頸部外科学分野

書誌事項

タイトル別名
  • Trastuzumab-based Chemotherapy for Metastatic Salivary Duct Carcinoma
  • 臨床 唾液腺導管癌に対するトラスツズマブの使用経験
  • リンショウ ダエキセン ドウカンガン ニ タイスル トラスツズマブ ノ シヨウ ケイケン

この論文をさがす

抄録

Introduction: The salivary duct carcinoma (SDC) is an uncommon aggressive malignant tumor of the salivary glands with frequent metastasis leading to a poor prognosis. SDC resembles high-grade breast ductal carcinoma and frequently overexpress human epidermal growth factor receptor-2 (HER-2). We report herein on a case of recurrent metastatic SDC treated with trastuzumab-based chemotherapy. A 77-year-old female was diagnosed as having a malignant tumor of the right parotid gland and underwent total parotidectomy and bilateral neck dissection. The resected tumor was histologically investigated and diagnosed as an SDC. No amplification of the HER-2 gene was found but overexpression of the HER-2 protein was detected (2+). Multiple metastases at the bilateral axillary and superior mediastinal lymph nodes were detected 10 months after surgery. We treated the patient with triweekly chemotherapy with a combination of trastuzumab and docetaxel for 4 cycles. However CT scan showed disease progression after chemotherapy. Conclusion: It is important to check out not only the overexpression of HER-2 protein with IHC, but HER-2 gene amplification also should be checked before trastuzumab-based chemotherapy for SDC.

収録刊行物

参考文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ